Foundever ® and Cognigy Strengthen Strategic Partnership to Deliver Scalable Agentic AI Solutions Across the Globe
10.6.2025 14:00:00 CEST | Business Wire | Press Release
Foundever®, a global leader in the customer experience (CX) industry, today announced an expansion of its long-term collaboration with Cognigy, a global leader in AI-powered customer service solutions, in bringing Agentic AI into full-scale production across enterprise CX environments. This partnership addresses the increasing demand from global brands for sophisticated AI solutions that offer proactive, autonomous service, going beyond basic automation to deliver secure, scalable, personalized and human-centric interactions.
By integrating the large-scale and global operational capabilities of Foundever with Cognigy's powerful Agentic AI, this partnership redefines the possibilities of automation, exceeding the limitations of traditional chatbots. In a truly Agentic CX environment, Foundever ensures AI agents work seamlessly alongside humans to create a real, integrated experience across diverse customer journeys. With conversational design built on a depth of experience managing over 3.3 billion customer interactions each year, Foundever brings operational processes and training to empower both AI and human agents. Using data to drive continuous improvements across all aspects of the customer experience, the combined capabilities of Foundever and Cognigy connect data, technology and human expertise in ways that deliver unmatched value.
As organizations rush to incorporate AI, the truth is clear: simply showcasing impressive demos is not enough. Together, Foundever and Cognigy are bridging this gap while accelerating the transition of AI-powered CX into real-world applications, demonstrating tangible, measurable results. The proactive approach and strategic insight that Foundever brings into operationalizing AI technology highlights its role as both a beneficiary and a creator of substantial value. This partnership, already trusted by Fortune 500 brands worldwide, paves the way from innovative ideas to widespread enterprise implementation.
“At Foundever, we are dedicated to delivering solutions that provide real value at scale,” stated Laurent Uberti, President, CEO & Founder of Foundever. “Our collaboration with Cognigy is centered around deploying Agentic AI that operates effectively in production, at scale, and across various channels. Together, we’re establishing a new standard for what AI can achieve in customer interactions—enhancing CX while driving significant operational efficiencies. Our clients can expect not just advanced technology but also improved customer satisfaction, reduced operational costs and the ability to respond faster to market changes.”
As part of this partnership, Cognigy’s platform will integrate into the global CX operations of Foundever, enabling the deployment of multilingual, autonomous AI agents across both voice and digital channels. Built for adaptability, security and scalability, Cognigy empowers organizations to move beyond trial phases and embark on impactful, measurable transformations that yield substantial returns on investment. This expanded partnership is about delivering solutions that result in faster response times and improved customer engagement, ultimately driving growth for clients of Foundever and Cognigy.
“This expanded partnership with Foundever marks a pivotal step in bringing Agentic AI into real-world CX at scale,” said Philipp Heltewig, CEO and Co-founder at Cognigy. “We’ve already seen the value of combining Foundever’s global CX delivery with Cognigy’s AI Agent platform — and now we’re accelerating that impact. Together, we’re proving that AI Agents can do more than just automate — they can transform the way enterprises serve customers across channels, languages, and geographies.”
The partnership’s continued success was recognized at Nexus 2025, Cognigy’s flagship AI summit, where Foundever received the “Most Unique Use Case” award in the Innovation Champions category. With over 750 attendees from global brands, the event celebrated companies leveraging Cognigy’s AI Agents to deliver exceptional CX and tangible business impact.
With Foundever and Cognigy leading the charge, the future of AI-driven customer experience is here—powered by intelligent technology and a commitment to innovation. For more information on Foundever and its initiatives, visit foundever.com.
About Foundever
Foundever® is a global leader in the customer experience (CX) industry. With 150,000 associates across the globe, we’re the team behind the best experiences for +800 of the world’s leading and digital-first brands. Our innovative CX solutions, technology and expertise are designed to support operational needs for our clients and deliver a seamless experience to customers in the moments that matter.
Supporting +9 million customer conversations every day in +60 languages across 45 countries, Foundever combines global strength and scale with the agile, entrepreneurial approach of our founder-led culture, enabling companies of all sizes and industries to transform their CX. Sitel Group and SYKES are now Foundever.
Get to know us at www.foundever.com and connect with us on Facebook, LinkedIn and X.
About Cognigy
Cognigy is transforming the customer service industry with the most advanced AI Agent platform for enterprise contact centers. Its award-winning solution, Cognigy.AI, empowers enterprises to deliver instant, hyper-personalized, multilingual service on any channel. By integrating Generative and Conversational AI to create Agentic AI, Cognigy delivers AI Agents that redefine customer experiences, drive satisfaction, and support contact center employees in real-time. Over 1,000 brands worldwide trust Cognigy and its vast partner network to create AI customer service agents for their contact center. Cognigy's impressive worldwide customer portfolio includes Bosch, Nestlé, DHL, Frontier Airlines, Lufthansa Group, Mercedes-Benz and Toyota.
For more information and to book a demo visit: www.cognigy.com. Follow the company on X (formerly Twitter) @Cognigy and on LinkedIn at https://www.linkedin.com/company/cognigy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610379651/en/
Contacts
Media contacts
Rebecca Sanders, Foundever
media@foundever.com
Cognigy
Cognigy@avenuez.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom